These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27342857)

  • 1. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.
    Liu Y; Gunda V; Zhu X; Xu X; Wu J; Askhatova D; Farokhzad OC; Parangi S; Shi J
    Proc Natl Acad Sci U S A; 2016 Jul; 113(28):7750-5. PubMed ID: 27342857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.
    Zhou M; Chen Y; Adachi M; Wen X; Erwin B; Mawlawi O; Lai SY; Li C
    Biomaterials; 2015 Jul; 57():41-9. PubMed ID: 25913249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics.
    Wang Q; Sui G; Wu X; Teng D; Zhu L; Guan S; Ran H; Wang Z; Wang H
    Acta Biomater; 2020 Jan; 102():367-383. PubMed ID: 31778831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostic poly(lactic-co-glycolic acid) nanoparticle for magnetic resonance/infrared fluorescence bimodal imaging and efficient siRNA delivery to macrophages and its evaluation in a kidney injury model.
    Yang C; Vu-Quang H; Husum DMU; Tingskov SJ; Vinding MS; Nielsen T; Song P; Nielsen NC; Nørregaard R; Kjems J
    Nanomedicine; 2017 Nov; 13(8):2451-2462. PubMed ID: 28842376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Tumor-Activatable Theranostic Nanomedicine Platform for NIR Fluorescence-Guided Surgery and Combinatorial Phototherapy.
    Li X; Schumann C; Albarqi HA; Lee CJ; Alani AWG; Bracha S; Milovancev M; Taratula O; Taratula O
    Theranostics; 2018; 8(3):767-784. PubMed ID: 29344305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
    Zhang K; Yu M; Hao F; Dong A; Chen D
    Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model.
    Lin Q; Jin CS; Huang H; Ding L; Zhang Z; Chen J; Zheng G
    Small; 2014 Aug; 10(15):3072-82. PubMed ID: 24706435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
    Hou L; Shan X; Hao L; Feng Q; Zhang Z
    Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein.
    Chiappetta G; Basile A; Arra C; Califano D; Pasquinelli R; Barbieri A; De Simone V; Rea D; Giudice A; Pezzullo L; De Laurenzi V; Botti G; Losito S; Conforti D; Turco MC
    J Clin Endocrinol Metab; 2012 Jan; 97(1):E115-20. PubMed ID: 22072743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
    Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
    Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer.
    Ng TSC; Gunda V; Li R; Prytyskach M; Iwamoto Y; Kohler RH; Parangi S; Weissleder R; Miller MA
    Radiology; 2021 Jan; 298(1):123-132. PubMed ID: 33107799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
    Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
    Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy.
    Xu X; Saw PE; Tao W; Li Y; Ji X; Yu M; Mahmoudi M; Rasmussen J; Ayyash D; Zhou Y; Farokhzad OC; Shi J
    Nano Lett; 2017 Jul; 17(7):4427-4435. PubMed ID: 28636389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
    Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L
    ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendrimer-Stabilized Gold Nanostars as a Multifunctional Theranostic Nanoplatform for CT Imaging, Photothermal Therapy, and Gene Silencing of Tumors.
    Wei P; Chen J; Hu Y; Li X; Wang H; Shen M; Shi X
    Adv Healthc Mater; 2016 Dec; 5(24):3203-3213. PubMed ID: 27901317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendrimer-encapsulated naphthalocyanine as a single agent-based theranostic nanoplatform for near-infrared fluorescence imaging and combinatorial anticancer phototherapy.
    Taratula O; Schumann C; Duong T; Taylor KL; Taratula O
    Nanoscale; 2015 Mar; 7(9):3888-902. PubMed ID: 25422147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
    Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
    Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
    Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
    J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
    Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
    Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma.
    Wang Y; Sui G; Teng D; Wang Q; Qu J; Zhu L; Ran H; Wang Z; Jin C; Wang H
    Biomater Sci; 2018 Dec; 7(1):196-210. PubMed ID: 30422139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.